Milestones In Basket Trials: Novartis' Ambitious SIGNATURE Program
Novartis' tissue-agnostic SIGNATURE trial uses eight of the company's drugs in an ambitious set of Phase II protocols that will be an important test of whether basket trial designs are useful in corporate oncology R&D programs.
You may also be interested in...
Merck's PD-1 inhibitor holds the first cancer indication based on biomarkers rather than tumor location. The most significant market will be colorectal cancer, but Bristol-Myers Squibb's Opdivo is pending for the same subgroup and Roche's Tecentriq could eventually gain a broader approval.
Robust natural history data sets with well-chosen outcomes are fundamental in Aetion’s regulatory feasibility tool for real-world evidence, built through analysis of US FDA case studies and guidance.
Takeda’s TAK-721 is back, ARS Pharma will be back soon to appeal neffy complete response letter, US FDA’s Project Renewal brings Temodar labeling in current day, and more highlights from the Pink Sheet’s US FDA Performance Tracker.